Envista Holdings Corporation (NVST) |
38.24 0.47 (1.24%)
|
03-24 16:00 |
Open: |
37.61 |
Pre. Close: |
37.77 |
High:
|
38.385 |
Low:
|
37.51 |
Volume:
|
1,044,821 |
Market Cap:
|
6,242(M) |
|
|
Technical analysis |
as of: 2023-03-24 4:28:26 PM |
Overall:
|
|
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
Target: |
Six months: 45.28 One year: 46.61 |
Support: |
Support1: 36.93 Support2: 30.72 |
Resistance: |
Resistance1: 38.77 Resistance2: 39.9 |
Pivot: |
38.22  |
Moving Average: |
MA(5): 38.3 MA(20): 38.37 
MA(100): 36.44 MA(250): 38.04  |
MACD: |
MACD(12,26): -0.1 Signal(9): -0.1  |
Stochastic oscillator: |
%K(14,3): 37 %D(3): 45.6  |
RSI: |
RSI(14): 49.4  |
52-week: |
High: 50.18 Low: 31.67 |
Average Vol(K): |
3-Month: 1,911 (K) 10-Days: 2,131 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NVST ] has closed below upper band by 49.5%. Bollinger Bands are 50.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
38.4 - 38.59 |
38.59 - 38.79 |
Low:
|
37.06 - 37.26 |
37.26 - 37.46 |
Close:
|
37.92 - 38.24 |
38.24 - 38.55 |
|
Company Description |
Envista Holdings Corporation, together with its subsidiaries, engages in the development, sale, and marketing of dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, and Orascoptic brands; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Insignia, AOA, and Spark brands. This segment also offers software packages, which include DTX Studio Implant for treatment planning of dental implants; TX Studio Lab for prosthetics treatment planning; and DTX Studio Clinic to store and access a various clinical patient images. The company's Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, sensors, software, and other visualization/magnification systems; endodontic systems and related consumables; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, Gendex, i-CAT, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California. |
Headline News |
Tue, 21 Mar 2023 Estimating The Intrinsic Value Of Envista Holdings Corporation (NYSE:NVST) - Simply Wall St
Wed, 15 Mar 2023 Envista Concludes its North America Envista Summit 2023, Opens ... - PR Newswire
Tue, 14 Mar 2023 Guru Fundamental Report for NVST - Martin Zweig - Nasdaq
Sat, 11 Mar 2023 Envista Holdings Co. (NYSE:NVST) Given Average Rating of ... - MarketBeat
Mon, 06 Mar 2023 Danaher: The Secret To Successful (Dividend) Investing (NYSE:DHR) - Seeking Alpha
Mon, 06 Mar 2023 Is It Time To Consider Buying Envista Holdings Corporation (NYSE:NVST)? - Simply Wall St
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Outperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Outperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: NYSE |
Sector: Healthcare |
Industry: Medical Instruments & Supplies |
Shares Out. |
163 (M) |
Shares Float |
163 (M) |
% Held by Insiders
|
0.2 (%) |
% Held by Institutions
|
116.1 (%) |
Shares Short
|
12,590 (K) |
Shares Short P.Month
|
13,070 (K) |
Stock Financials |
EPS
|
1.29 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
25.78 |
Profit Margin (%)
|
9.4 |
Operating Margin (%)
|
14.1 |
Return on Assets (ttm)
|
3.4 |
Return on Equity (ttm)
|
5.7 |
Qtrly Rev. Growth
|
1.3 |
Gross Profit (p.s.)
|
9.12 |
Sales Per Share
|
15.74 |
EBITDA (p.s.)
|
3.07 |
Qtrly Earnings Growth
|
-13.2 |
Operating Cash Flow
|
183 (M) |
Levered Free Cash Flow
|
217 (M) |
Stock Valuations |
PE Ratio
|
29.41 |
PEG Ratio
|
1.9 |
Price to Book value
|
1.48 |
Price to Sales
|
2.42 |
Price to Cash Flow
|
34.16 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|